PMID- 26618756
OWN - NLM
STAT- MEDLINE
DCOM- 20160929
LR  - 20160205
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 16
IP  - 2
DP  - 2016
TI  - The role of hyperthermia as a treatment for non-muscle invasive bladder cancer.
PG  - 189-98
LID - 10.1586/14737140.2016.1126515 [doi]
AB  - Non-muscle invasive bladder cancer (NMIBC) has a high tendency for recurrence and 
      progression. Currently, all known intravesical agents are associated with adverse 
      effects (AEs) and limited efficacy. The combination of hyperthermia (HT) with 
      intravesical Mitomycin C (MMC) chemotherapy has been shown to improve outcomes. 
      The added efficacy of HT to MMC was first shown in preclinical studies. The 
      reports on patients with NMIBC have indicated that the treatment is safe and well 
      tolerated. Several clinical studies reported the efficacy of 
      radiofrequency-induced chemotherapy effect (RITE) in the treatment of patients 
      with NMIBC. This modality was shown to be superior to MMC alone. RITE was 
      effective also in patients with high-risk NMIBC, including those who failed 
      Bacillus Calmette-Guerin (BCG). This study provides an updated review of 
      literature regarding the use of RITE in patients with NMIBC.
FAU - Bahouth, Zaher
AU  - Bahouth Z
AD  - a Department of Urology, Bnai-Zion Medical Center, Faculty of Medicine , 
      Technion- Institute of Technology , Haifa , Israel.
FAU - Halachmi, Sarel
AU  - Halachmi S
AD  - a Department of Urology, Bnai-Zion Medical Center, Faculty of Medicine , 
      Technion- Institute of Technology , Haifa , Israel.
FAU - Moskovitz, Boaz
AU  - Moskovitz B
AD  - a Department of Urology, Bnai-Zion Medical Center, Faculty of Medicine , 
      Technion- Institute of Technology , Haifa , Israel.
FAU - Nativ, Ofer
AU  - Nativ O
AD  - a Department of Urology, Bnai-Zion Medical Center, Faculty of Medicine , 
      Technion- Institute of Technology , Haifa , Israel.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20151219
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 50SG953SK6 (Mitomycin)
SB  - IM
MH  - Administration, Intravesical
MH  - Animals
MH  - Antibiotics, Antineoplastic/administration & dosage/adverse effects/therapeutic 
      use
MH  - Combined Modality Therapy
MH  - Humans
MH  - Hyperthermia, Induced/adverse effects/*methods
MH  - Mitomycin/*administration & dosage/adverse effects/therapeutic use
MH  - Treatment Outcome
MH  - Urinary Bladder Neoplasms/pathology/*therapy
OTO - NOTNLM
OT  - Radiofrequency induced chemotherapy effect (RITE)
OT  - chemo-hyperthermia
OT  - hyperthermia
OT  - intravesical chemotherapy
OT  - mitomycin C
OT  - non-muscle invasive bladder cancer
EDAT- 2015/12/01 06:00
MHDA- 2016/09/30 06:00
CRDT- 2015/12/01 06:00
PHST- 2015/12/01 06:00 [entrez]
PHST- 2015/12/01 06:00 [pubmed]
PHST- 2016/09/30 06:00 [medline]
AID - 10.1586/14737140.2016.1126515 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2016;16(2):189-98. doi: 
      10.1586/14737140.2016.1126515. Epub 2015 Dec 19.